Investing

Tesla TSLA Stock News

Tesla Inc (NASDAQ: TSLA) is having a relatively strong start to the trading session, and for good reason. Elon Musk surprised investors with the unveiling of a new car, and that care is a big game changer. Today, we’ll talk about the new product offering, how the stock is reacting to the news, and what we’ll be watching for with regard to TSLA ahead.





TSLA Unveils Its New Roadster

As mentioned above, late yesterday after hours, Tesla surprised investors when Elon Musk unveiled a new roadster. The new vehicle wasn’t only a surprise, it’s a first in its class offering. The new vehicle, known as the Roadster is a record-breaking car as soon as it comes off of the line.

In fact, the TSLA Roadster will be the fastest production vehicle on the road. The car is capable of going from 0 to 60 in just 1.9 seconds; breaking the 2 second barrier for the first time ever in a production vehicle.




However, if you want a Roadster from TSLA, you’re going to have to pay for it. The car comes with a base price of $200,000. At the moment, you can reserve one of these vehicles for $50,000. If you want to go up a notch, Tesla is also launching the Founders Series Roadsters. These vehicles will be limited to the first 1,000 reservations and comes with a price of $250,000.

The game changing part of this is that this isn’t only going to be the fastest production vehicle on the road. As with all TSLA vehicles, the Roadster is an electric car. The fact that the car can go from 0 to 60 in 1.9 seconds and doesn’t burn gasoline to do so is absolutely astounding and what Elon Musk calls a smackdown to gasoline powered vehicles.

How The Stock Is Reacting To The News

As investors, we’ve come to expect that when positive news is released surrounding a publicly traded company, we can expect to see gains in the value of the stock that represents the company. That’s exactly what we’re seeing out of Tesla today. With the new product offering on the minds of investors, the stock is making a run for the top. At the moment (9:06), TSLA is trading at $325.87 per share after a gain of $13.37 per share or 4.28% thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on TSLA. In particular, we’re interested in following the story surrounding the Roadster and excited to see how many of the new vehicles are sold. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









China Advanced Construction Materials Group Inc CADC Stock News

China Advanced Construction Materials Group Inc (NASDAQ: CADC) is having an incredibly strong day in the market today after releasing their earnings report for the third quarter. Today, we’ll talk about what we saw from the report, how the stock is reacting to the news, and what we’ll be watching for with regard to CADC ahead.





CADC Reports Earnings

As mentioned above, China Advanced Construction Materials Group is having an incredibly strong day in the market today after reporting its earnings for the third quarter. Here’s what we saw from the earnings report:




  • Revenue – In terms of revenue, CADC did overwhelmingly well. During the quarter, the company generated revenue of about $13.8 million. That’s a massive improvement year over year from $7.5 million. The increase in revenue is largely due to an increase in sales volume of 56% as a result of customers expediting their construction progress before the severe winter ahead. Also, an increase in the selling price of concrete by 19% played a key role in the increased revenue.
  • Cost Of Revenue – Total cost of revenue came in at about $12.3 million. That figure proved to increase by 47% as a result of an increase of production volume. However, the cost was offset by a decrease in the unit production cost of 19%.
  • Gross Profit – Finally, gross profit came in at approximately $1.4 million. That’s compared to a $1 million gross loss in the same quarter 1 year ago.

The company pointed to their ability to continue at a strong pace due to the following factors:

  • Large-Scale Contractor Relationships – CADC informed investors that they have contracts with major construction contractors that are key to infrastructure, commercial and residential projects. With a sales effort focused on large-scale products and large customers, the company operates with less risk.
  • Management – CADC also reminded investors that the management team has vast experience; providing technical knowledge and business relationships that give them an upper hand in the market.

In a statement, the company offered the following:

Our management believes that we have the ability to capture a greater share of the Beijing market via expanding relationships and networking, signing new contracts, and continually developing market-leading innovative and eco-friendly ready-mix concrete products.”

What We’re Seeing From The Stock

At the end of the day, strong earnings tend to cause strong movements in the market. However, no one could have expected the massive gains we’re seeing out of this one. Of course, our partners were the first to alert us to the movement. At the moment (11:14), CADC is trading at $7.90 per share after a gain of $5.70 per share or 259.09% thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on CADC. In particular, we’re interested in following the company’s ongoing innovation in the building materials sector. We’re also interested in seeing if the large-scale efforts will bear fruit when it comes to maintaining growth through winter. Nonetheless, we’ll continue to follow the story and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Meridian Waste Solutions MRDN Stock News

Meridian Waste Solutions Inc. (NASDAQ: MRDN) is having an overwhelmingly strong day in the market today, and for good reason. The company announced earnings as well as lobbying efforts, both of which are exciting investors. Today, we’ll talk about the news, how the stock is reacting, and what we’ll be watching for with regard to MRDN ahead.





MRDN Announces Earnings

As mentioned above, Meridian Waste Solutions is having an incredibly strong day in the market today. A Big part of the gains has to do with the financial results that were announced yesterday. Here’s what we saw from the report:




  • Revenue – During the quarter, MRDN saw impressive growth in revenue. In fact, quarterly revenue came in at $14.8 million. That’s an increase of 77% compared to the third quarter of 2016. The company said that the growth was primarily due to the acquisition of the CFS Group. Nonetheless, organic revenue growth was also an impressive 9.0%.
  • Operating Expensive – MRDN also reported an impressive decline in operating expenses as a percentage of revenue. In fact, in the third quarter, operating expenses came in at 70% of revenue. That’s a big drop from the 80% figure we saw in the second quarter.
  • EBITDA – Finally, Meridian Waste Solutions said that Adjusted EBITDA came in at $3.4 million for the core waste management and services segment, in relation to interest expense of $2.7 million.

In a statement, Jeff Cosman, Chairman and CEO at MRDN, had the following to offer:

We continue to integrate and improve efficiencies in our Mid-Atlantic segment, particularly our Virginia assets, and uncover ways to improve margins. Thanks to being able to access the capital markets for an additional $5 million over the past few months, we have been able to deploy new equipment in Virginia to be able to improve our operating efficiencies and margins. It is these developments and processes that increase our value for the longer-term. We continue to look for growth opportunities in all areas of our waste operations; the core platform of waste management and services and the emerging growth innovations and technology… We are very enthused about what we have assembled with Innovations and look forward to sharing our progress with the markets in the near future.”

Lobbying Efforts

After announcing earnings yesterday, MRDN also released a press release this morning. In the press release, the company announced that it’s wholly owned subsidiary, Meridian Innovations, has made some efforts on the lobbying front. According to the PR, the company attended the quarterly Biomass Research and Development meeting in Washington, D.C., providing a formal public comment to the Technical Advisory Committee. The comment was aimed at urging the committee to continue its support of government-funded opportunities for biomass feedstock and bio-based product research and development. In a statement, Jeff Cosman, CEO at MRDN, had the following to offer:

Attis Innovations believes heavily in the role of government agencies to provide guidance and funding opportunities for the development of biobased products… We believe the combination of Attis Innovations revolutionary technology portfolio and the support of government advisory entities like the Biomass Research and Development Board will propel the US towards the reduction of fossil fuels and create countless green collar jobs that will support the US bioeconomy.”

What We’re Seeing From MRDN

As we’ve come to expect any time we see strong earnings out of a publicly traded company, Meridian Waste Solutions is having an incredible day in the market today. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (10:37), MRDN is trading at $2.30 per share after a gain of $0.88 per share or 62.30% thus far today.

Stop wasting your time. Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on MRDN. In particular, we’re interested in following the story surrounding the company’s ongoing work in biomass innovation while revenue from the company’s core services business continues to grow. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Youngevity International YGYID Stock News

Youngevity International Inc (NASDAQ: YGYI) is having a relatively strong start to the trading session this morning after the company announced that its wholly owned subsidiary, CLR Roasters, has collaborated with the Marlins Foundation. Today, we’ll talk about the collaboration, what we’re seeing form the stock, and what we’ll be watching for with regard to YGYI ahead.





YGYI Announces Collaboration

As mentioned above, Youngevity International is having a relatively strong start to the trading session this morning after announcing a collaboration. CLR Roasters, a wholly owned subsidiary of the company, has entered into a collaboration with the Marlins Foundation to donate one thousand Thanksgiving meals to families in local Miami neighborhoods.




Under the collaboration CLR Roaster’s Cafe La Rica Espresso Brand as well as local community partners, including Feeding South Florida, Pepsi, Goya Foods, and Presidente Supermarkets will work with the Florida Marlins to provide the ninth annual Thanksgiving Distribution on Marlins Park on November 17. During the event, families will include a 10-pound turkey, fixings, Cafe La Rica Coffee and desert. The event is an exclusive event for pre-selected families as well as the media. In a statement, YGYI President and CEO, Dave Briskie, had the following to offer:

When Café La Rica was selected to become the “Official Cafecito” of the Florida Marlins part of the consideration given to us being chosen for this partnership was our involvement with our own Youngevity Be the Change Foundation’s charitable work. We are proud to stand alongside the Florida Marlin’s and their foundation to join in their commitment of being socially responsible within their own community.”

The above statement was followed up by Ernesto Aguila, President at CLR Roasters. Here’s what he had to say:

We all cherish spending time with loved ones and enjoying delicious food during this special holiday. That’s why we’re so thrilled to partner with The Marlins Foundation and the other incredible companies that have joined together to provide these local families with a true Thanksgiving feast.”

What We’re Seeing From The Stock

As mentioned above, Youngevity International is having a relatively strong day in the market today. At the moment (9:30), YGYI is trading at $4.64 per share after a gain of $0.03 per share or 0.65% thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on YGYI. In particular, we’re interested in watching the continued growth of CLR Roasters as well as the rest of the company’s robust offering of brands. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 283
Pernix Therapeutics Holdings PTX Stock News

Pernix Therapeutics Holdings Inc (NASDAQ: PTX) is having a relatively strong start to the trading session this morning after the company announced that it has hired two new directors to its Board. This led to excitement among investors who are pushing the stock up. Today, we’ll talk about the new board additions, what we’re seeing from the stock as a result, and what we’ll be watching for with regard to PTX ahead.





PTX Hires New Board Members

As mentioned above, Pernix Therapeutics is in the green early on this morning after the company announced that it has hired 2 new board members. The new members include John R. Leone and Douglas J. Swirsky. The company’s Board has five members total. Four of the members of the Board are independent as incumbant directors. Also, the company announced that Graham Miao, Ph.D. And Tasos Konidaris do not stand for re-election.




The first new Board member, John R. Leone is currently serving as Operating Partner at Madryn Asset Management. Mr. Leon has also served as a Partner at Visium Asset Management from May of 2013 to January of 2017. He has also held leadership positions at Paul Capital Healthcare, Cambrex Corporation, Aventis Pharmaceuticals and Windtree Therapuetics, bringing a vast amount of industry experience to PTX.

The second new Board member, Douglas J. Swirsky was most recently the CEO and director at GenVec. He has also held positions at Stifel Nicolaus, Legg Mason, UBS, PaineWebber, Morgan Stanley, Fibrocell Science and Cellectar Biosciences.

In a statement, John Sedor, Chairman and CEO at PTX, had the following to offer:

We are pleased to welcome Doug and John to our Board… They both have a wealth of healthcare industry-related operating and capital markets expertise experience. We look forward to their strategic contributions as we continue to grow our core product brands and seek new acquisition opportunities.

On behalf of the Board, I would also like to take this opportunity to thank Graham and Tasos for their valued support through their tenures as Board members… We wish them well in their future endeavors.”

How The Stock Is Reacting

It’s clear that Pernix Therapeutics investors are happy about the new hires. That’s because they are pushing the stock to the green this morning. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (9:41), PTX is trading at $3.05 per share after a gain of $0.05 per share or 1.67% thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on PTX. In particular, we’re interested in following the company to see what the two new board members bring to the table. We’ll also be keeping a close eye on the continued growth of Zohydro as well as the rest of the brands in the company’s robust product offering. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 390
Synergy Pharmaceuticals Inc SGYP Stock News

Synergy Pharmaceuticals Inc (NASDAQ: SGYP) had a rough day in the market yesterday, falling more than 10% throughout the day and closing down more than 6%. However, today the stock seems to be making a recovery in the pre-market hours. Today, we’ll talk about what we’re seeing from SGYP, the story surrounding the stock, and what we’ll be watching for ahead.





What We’re Seeing From SGYP

As mentioned above, Synergy Pharmaceuticals has been a bit of a roller coaster ride over the past few trading sessions. While the stock closed the day down more than 6% yesterday, it’s trading up in a strong way in the pre-market hours this morning. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (9:04), SGYP is trading at $1.95 per share after a gain of $0.06 per share or 3.17% thus far today.




The Synergy Pharmaceuticals Story

Synergy Pharmaceuticals is a company that’s focused on addressing gastrointestinal conditions. In particular, the company has a flagship product, known as Trulance (Plecanatide), that is indicated for the treatment of chronic idiopathic constipation (CIC) as well as irritable bowel syndrome with constipation (IBS-C). At the moment, the company has achieved approval from the FDA for the CIC constipation and has a New Drug Application in with the FDA surrounding the IBS-C indication.

However, investors have found themselves stuck in the middle on this one. While SGYP has achieved FDA approval for one indication and is likely to expand its label to include IBS-C in January, the financial picture isn’t a pretty one. With a cash burn rate of around $60 million a quarter and revenue around $5 million, SGYP is blowing through money and could burn through its cash on hand within a couple of quarters. While there is a $300 million credit facility the company can take advantage of, pulling money from this facility comes at a high cost with a 9.5% interest rate. So, the financial picture is a pretty dim one at the moment.

The Silver Lining

There is a silver lining here. Sure the financial picture for Synergy Pharmaceuticals isn’t the greatest one at the moment. However, sales are climbing at an incredible rate. In fact, most recent numbers showed that Trulance sales grew by more than 100%, and the company is expecting for this growth to continue.

One of the keys here has been a rapid increase in payer coverage. In fact, SGYP has coverage with both private and public insurance companies, and continues with their efforts to expand this coverage. As coverage continues to expand, sales are likely to continue to grow at an astounding rate. Then, when we add in the likely FDA approval of the label change to add IBS-C as an indication on the Trulance label, the opportunity becomes more clear. While it will take some time, SGYP rapid sales growth could push the company to a profit in the future.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on SGYP. In particular, we’re watching two big stories. First and foremost, the sales growth story is a great one, and we’re hoping that it continues on this path. Also, we have the PDUFA date for the IBS-C indication coming in January, which is just around the corner. Considering the positive data produced through clinical trials, this approval is likely.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 548
Rosetta Genomics Ltd. (USA) ROSG Stock News

Rosetta Genomics Ltd. (USA) (NASDAQ: ROSG) is having an overwhelmingly strong start to the trading session in the pre-market hours this morning, and for good reason. The company recently released a corporate update with some exciting news surrounding RevealTM. Today, we’ll talk about the data, how the stock is reacting to the news, and what we’ll be watching for with regard to ROSG ahead.





ROSG Gains On Update

As mentioned above, Rosetta Genomics is having an incredibly strong start to the trading session in the pre-market hours after the company released new information via an updated slide deck. The information surrounds RevealTM, the company’s proprietary microRNA-based test designed to identify benign thyroid modules. Here are the key points from the release:




  • Revenue Growth – ROSG said that the company has seen exceptional revenue growth since the launch of the product back in 2016. This is ultimately the result of the offering’s convenience and performance advantages compared to other products.
  • Revenue Total – In the first half of the year 2017, ROSG generated $1.2 million in revenue from the product. That’s a 600% increase when compared to the first half of 2016. Also in the third quarter of 2017, preliminary revenues from Reveal came in at $0.86 million!
  • Sales Plans – Rosetta Genomics also said that it has committed to a plan to sell Pdx businesses. Ultimately, this decision was based on a $350 million market opportunity in the United States alone.
  • Studies – Finally, ROSG is in the midst of various studies to support demand growth and continue to improve reimbursement coverage.

How The Stock Is Reacting To The News

As you could imagine, with Rosetta Genomics announcing a 600% increase in sales revenue, investors are excited. Of course, the stock is flying as a result. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. At the moment (8:46), ROSG is trading at $0.92 per share after a gain of $0.13 share or 16.47% thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on ROSG. In particular, we’re interested in following the ongoing story surrounding the company’s Reveal product, and we’re excited to continue following the growth. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Wal-Mart Stores Inc WMT Stock News

Wal-Mart Stores Inc (NYSE: WMT) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The company announced its earnings for the third quarter, blowing away expectations and causing excitement among investors. Today, we’ll talk about what we saw from earnings, how the stock is reacting to the news, and what we’ll be watching for ahead.





What We Saw From WMT Earnings

As mentioned above, Wal-Mart Stores is having an incredibly strong start to the trading session in the pre-market hours this morning after the company released its financial results for the third quarter. Of course, the results were overwhelmingly positive. Here’s what we saw from the report:




  • Earnings Per Share – In terms of earnings per share, WMT did overwhelmingly well. During the quarter, analysts expected that the company would generate earnings in the amount of $0.97 per share. However, the company actually reported earnings in the amount of $1.00 per share, beating expectations.
  • Revenue – Revenue also proved to be a positive notch on the belt for the company. During the quarter, analysts expected that WMT would generate revenue in the amount of $121.04 billion. However, the company actually produced revenue in the amount of $123.18 billion, once again beating expectations.
  • Sales – In terms of eCommerce sales, Wal-Mart did great yet again. During the quarter, the company saw a 50% increase in eCommerce sales. On the same store sales side, more good news was released. While analysts expected that same store sales would increase by 1.9%, the company actually announced an increase in same store sales in the amount of 2.7%.
  • Guidance – Finally, based on the strong quarter, WMT increased its guidance for the fiscal 2018 year. During the year, the company expects to produce earnings in the range between $4.38 per share and $4.46 per share. That’s up from between $4.30 per share and $4.40 per share.

How The Stock Is Reacting To The News

As investors, we’ve come to expect that when earnings expectations are beat, we can expect to see gains in the stock. That’s exactly what we’re seeing this morning. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (8:16), WMT is trading at $93.86 per share after a gain of $4.03 per share or 4.49% thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on WMT. In particular, we’ll continue to follow the growth in eCommerce and same-store sales. We’re also interested in seeing if Wal-Mart does indeed meet the high expectations for fiscal 2018 that it has set for itself. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Aytu Bioscience Inc AYTU Stock News

Aytu BioScience has been on a roll, raising investor eyebrows from the growth of Natesto®, the company’s testosterone replacement therapy treatment. Investors following that story know that Natesto® is recording robust and sequential increases in new prescription and factory orders of over 300% since the second quarter of the fiscal year 2017, and a more than 411% increase over the same quarter in 2017. However, slightly hidden by the fanfare from Natesto® is MiOXSYS®, AYTU’s novel, rapid semen analysis system that is gearing up to become the standard of care diagnostic system designed to assess male infertility caused by oxidative stress. And, it’s time that MiOXSYS® grabs some more attention.

MiOXSYS®, another approved for market treatment offered from AYTU, is already commercialized outside the U.S. market, capitalizing on its status as a CE Marked, Health Canada cleared product. But, don’t worry, AYTU is not planning to ignore the vast potential of the U.S. market and is in the process of finalizing plans to initiate U.S.-based clinical trials in pursuit of 510(k) medical device clearance by the FDA. For AYTU, MiOXSYS® compliments the strategic plan of optimizing its portfolio of revenue-generating urology products, leveraging off the expertise of its management team that has shown success in building and bringing to market leading brands in specialized, multi-billion dollar markets.

More Good News For MiOXSYS®

Last week, AYTU announced that the Australian Therapeutic Goods Administration granted market approval to the MiOXSYS® system for inclusion on the Australian Register of Therapeutic Goods. The approval acknowledges the value of MiOXSYS® as a viable and reliable tool in the diagnostic assessment of semen quality for patients undergoing male infertility evaluation.

For AYTU, this latest approval by the TGA adds to the placement momentum and positions MiOXSYS® to take advantage of the one in six couples in Australia that suffer from infertility, with an estimated 50% of the cases attributed to male factor infertility. The approval permits AYTU to strategically penetrate the Australian markets to identify and help treat men with suspected infertility where oxidative stress is implicated.

The approval further lays the foundation for AYTU management to expedite its strategic plans to develop targeted sectors of the Australian markets, with management guiding toward the likelihood of adding distribution partners that can further introduce the MiOXSYS® system for clinical use in the coming quarters. Once the agreements get finalized, MiOXSYS® will advance the AYTU pipeline of revenue-generating products addressing multi-billion dollar opportunities, with limited exposure to regulatory pressures that its competitors face by being mired in mid to late-stage clinical trials. For AYTU, the MiOXSYS® system offers the market more than just a new system. The MiOXSYS® solution provides the most comprehensive, state-of-the-art diagnostic designed to generate results almost immediately. And, in most cases, the test can be administered by an office technician, a stark departure from current testing practices that often require well-trained professionals and several hours, or even days of analysis before providing the patient with test results.

MiOXSYS® Is Transformative To Current Standard of Care

Beyond its advantages in speed and accuracy, the MiOXSYS® system offers a solution from the need of expensive and sometimes bulky set-ups that have historically produced unreliable oxidative stress level results, often generated from these now antiquated and difficult-to-use systems.

For practitioners, investing in the latest and most efficient device, MiOXSYS®, will help to alleviate practice disruptions, limiting unreliable oxidative stress level results associated with the use of competitive devices. Beyond generating reliable data, the MiOXSYS® system can provide complete oxidative stress testing quickly, a significant advantage to what has historically taken several hours to complete. The MiOXSYS® test requires no specialized training for administration, can go from box to patient in a matter of minutes, and provides a comprehensive set of results in less than five minutes. The results provide rapid, reliable measures for oxidative stress levels. The importance of determining oxidative stress levels is critical to the clinician, who can target specific treatments to lower oxidative stress and increase the chances of pregnancy.

The Impact Of A Successful Launch

For AYTU investors, management has guided toward an achievable goal, which is to place an estimated 200 MiOXSYS® systems worldwide by the end of 2018. Currently, 96 systems are in use around the world. Once the goal gets met, management expects that each system may generate roughly of $20,000 per year each, totaling to an estimated revenue run rate more than $4 million in annual sales. Utilizing the razor-razorblade sales model, AYTU, or its licensed partners, would provide the disposable components required for each test, allowing the MiOXSYS® system to continuously generate revenue with a low cost, high-margin business model.

Keep in mind that while these projections would deliver a substantial spike in the revenue run rate, they do not include the potential from United States distribution. Management knows this better than anyone, and they are working toward a successful 510(k) medical device FDA approval, which would increase the market opportunity substantially, likely causing the placement projections to get revised sharply higher. And, for those that doubt the effectiveness of the MiOXSYS® system, no less than six papers have been published in prominent peer-reviewed journals and publications that substantiate the system’s value for providing a detailed, accurate, and reliable representation of male infertility analysis.

For AYTU and their investors, the most recent Australian expansion serves as another stepping stone toward a worldwide placement with a game-changing technology. Acknowledging that company management is cultivating significant growth rates for Natesto® units sold and its prescriber base, investors have the right to feel confident that similar quantifying results for MiOXSYS® will get achieved. For those that are familiar with AYTU prowess, the latest MiOXSYS® territory approval is a welcome accomplishment, but at the same time expected. However, for those new to the story, it’s suggested that time gets spent learning about the management team and their proven track record of product development and market success.

Once aware of the team’s prior and developing accomplishments, as well as getting to know the accretive product portfolio beginning to make its presence known to the market channels, investors may be wise to consider purchasing shares at these low levels. After all, taking early advantage of AYTU’s future by realizing the potential from Aytu BioScience’s disruptive and revolutionary products may inevitably lead to long-term success, adding considerable shareholder value from AYTU finding its place as a leader in several multi-billion dollar markets.

Northern Dynasty Minerals Ltd NAK Stock News

Northern Dynasty Minerals Ltd (NYSEAMERICAN: NAK) has been an interesting stock to watch over the past couple of years. A couple of years ago, I would have said that the risks were too high to get involved. However, my opinion is far different today. I now believe that the stock provides an opportunity that comes with massive potential and minimal risk. Today, we’ll talk about the potential, the fact that risk has been largely minimized, what we’re seeing from the stock today, and what we’ll be watching for with regard to NAK ahead.





The Potential Opportunity Surrounding NAK

As mentioned above, Northern Dynasty Minerals is currently offering the potential for massive long-run gains. At the end of the day, this potential revolves around the company’s primary venture known as the Pebble Project.

The Pebble Project, located in Alaska, is one of the largest stores of mineral wealth ever discovered. In fact, considering current resource estimates, the Pebble Project is the world’s largest undeveloped copper and gold resource at this time. However, these are not the only resources that the company will have access to once the mine is up and running.




In fact, current resource estimates suggest that there are billions of tonnes of copper, gold, molybdenum, and silver located under the surface at the mine. At the end of the day, if NAK does access these resources, it will be sitting on a literal and figurative gold mine with the ability to pull massive amounts of basic materials out of the earth.

This alone is a big opportunity. However, looking into NAK stock, the opportunity becomes even more clear. Over the past five years, the value of the stock has seen dramatic declines as the company battled with the EPA to obtain the ability to file for permits. While the stock has come back from lows, it is still priced at an incredible discount due to years of declines. So, not only is there an opportunity to get in on one of the world’s largest mines, that opportunity comes at a discount!

Minimal Risk

As mentioned above, if you would have asked me about Northern Dynasty Minerals a couple of years ago, I would have told you to stay away. That’s because the company was in a battle with the EPA and it seemed like they would never be able to apply for permits for the Pebble Project. However, that has changed in a big way.

Earlier this year, it was announced that NAK and the EPA had reached a settlement. Under the terms of the settlement agreement, the company was given a clear path to permitting. Essentially, the company had to prove that the Pebble Project would not have a negative effect on the environment in which it sits.

For several months, NAK has been working to prove this, and it has largely done so. Recently, the company announced plans surrounding the Pebble Project that put several environmental safeguards in place. On top of that, the company outlined the economic benefits the mine would have on the community in which it sits. Chances are that approval will be a breeze due to these plans.

On top of that, the company recently announced the hiring of Mark Hamilton. Hamilton is a key figure in the Alaskan community, and he will likely make the permitting process even easier than it seems to have become.

Finally, while the risks have been reduced greatly, they’re likely to be reduced further. Recently, Northern Dynasty Minerals has been hinting at partnerships. In fact, many, including myself, believe that the fact that the company has hired Hamilton is a sign that partnerships are all but signed, sealed, and delivered. These partnerships will further minimize risk for NAK and its shareholders.

What We’re Seeing From The Stock Today

As investors continue to await news of partnerships, excitement continues to grow. In fact, the stock is having another strong day in the market today. Of course, our partners at Trade Ideas were the first to alert us to the gains. Currently (9:01), NAK is trading at $2.23 per share after a gain of $0.06 per share (2.76%) thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on NAK. In particular, we’re interested in following the ongoing permitting process of the Pebble Project and excited to see the company move to the development phase. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Thought Leader Discussions

Gevo, Inc. GEVO Stock News

0 7180
Gevo, Inc. (NASDAQ: GEVO) Before we get into this interview, I'd like to extend a special thanks to my friend Joey who both set up the...